Gemcitabine for Classical Hodgkin's Lymphoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000400

Enrollment

Unknown

Registered

2009-05-27

Start date

2009-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hodgkin's Lymphoma

Interventions

Treatment Group:The chemotherapy plan is the same with the control group.In addition to ABVD therapy, Gemcitabine 900mg/m2 will be added on Day 1 and 15 for each coursed.

Control Group:ABVD chemotherapy. For stage II patients, 6 courses of ABVD chemotherapy are planned. For Stage III and IV patients. 8 coursed of ABVD chemotherapy are planned.

Eligibility

Sex/Gender

All

Age

12 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Previously untreated nodular sclerosis type Hodgkin's Lymphoma stage at IIB or IIIA or higher; 2. Previously untreated mixed cell type or lymphocyte depleted type Hodgkin's lymphoma at stage II.

Exclusion criteria

Exclusion criteria: 1. Nodular lymphocyte dominant type Hodgkin's Lymphoma; 2. Any type Hodgkin's Lymphoma at stage I.

Design outcomes

Primary

Measure	Time frame
CR rate;Overall Survival;	—

Secondary

Measure	Time frame
DFS;TTP;	—

Countries

China

Contacts

Public ContactYongqian Jia

jia_yq@scu.edu.cn+86 028 81812242

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026